Related Experiment Video
Updated: Apr 12, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.5K
Advances in gene therapy for heart failure.
Kenneth M Fish1, Kiyotake Ishikawa
1Cardiovascular Research Center, Ichan School of Medicine at Mount Sinai, New York, NY 10029, USA.
Discovery Medicine
|May 16, 2015
Summary
Cardiac gene therapy using adeno-associated virus (AAV) vectors shows promise for treating chronic heart failure. Current clinical trials and preclinical studies highlight AAV-SERCA2a as a leading approach for advanced heart failure patients.
Area of Science:
- Cardiology
- Molecular Medicine
- Biotechnology
Background:
- Chronic heart failure (CHF) presents a growing socioeconomic burden due to increased patient survival.
- Limited treatment options exist for CHF patients, necessitating novel therapeutic strategies.
- Adeno-associated virus (AAV) vectors have become the preferred choice for cardiac gene therapy, advancing clinical and preclinical research.
Purpose of the Study:
- To review current gene therapy approaches for heart failure.
- To highlight therapies in clinical trials or nearing clinical application.
- To focus on AAV-based strategies for chronic advanced heart failure.
Main Methods:
- Review of clinical trials and preclinical studies in cardiac gene therapy.
- Focus on adeno-associated virus (AAV) vector applications.
- Examination of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) gene therapy.
Main Results:
- Significant progress in clinical translation of cardiac gene therapy.
- AAV-1 mediated SERCA2a gene therapy shows promise for advanced CHF.
- Successful gene therapy approaches demonstrated in large animal models.
Conclusions:
- Cardiac gene therapy, particularly with AAV vectors, offers a promising avenue for CHF treatment.
- SERCA2a gene therapy is a frontrunner for advanced heart failure.
- Further clinical translation is anticipated based on successful preclinical data.
Related Concept Videos
00:59Gene Therapy
28.2K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
28.2K
00:59Gene Therapy
4.8K
4.8K
01:29Heart Failure II: Pathophysiology
1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
01:17Pathophysiology of Heart Failure
4.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.7K
01:30Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
01:22Heart Failure VI: Adjunct Therapies
599
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
599